<DOC>
	<DOCNO>NCT00083070</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , temozolomide , work different way stop cancer cell divide stop grow die . PURPOSE : This phase I trial study side effect best dose temozolomide treat young patient refractory recurrent leukemia .</brief_summary>
	<brief_title>Temozolomide Treating Young Patients With Refractory Recurrent Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose recommended phase II dose temozolomide pediatric patient refractory recurrent leukemia . - Determine toxic effect drug patient . - Determine pharmacokinetics drug patient . Secondary - Determine antitumor activity drug patient . - Determine biologic activity mechanism ( ) resistance drug patient . OUTLINE : This open-label , dose-escalation , multicenter study . Patients receive oral temozolomide daily day 1-5 . Treatment repeat every 28 day 12 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos temozolomide maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : A total 3-36 patient accrue study within 18-24 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm leukemia follow type : Acute lymphoblastic leukemia Acute myeloid leukemia Chronic myelogenous leukemia blast crisis Refractory recurrent disease Immunophenotypic confirmation disease initial diagnosis recurrence More 25 % blast bone marrow ( M3 ) Active extramedullary disease allow except leptomeningeal disease No known curative therapy therapy proven prolong survival acceptable quality life No active CNS disease PATIENT CHARACTERISTICS : Age 1 21 Performance status Karnofsky 50100 % ( patient &gt; 10 year age ) Lansky 50100 % ( patient ≤ 10 year age ) Life expectancy Not specify Hematopoietic WBC &lt; 30,000/mm^3 ( hydroxyurea leukapheresis allow discretion principal investigator ) Platelet count ≥ 20,000/mm^3 ( platelet transfusion allow ) Hemoglobin ≥ 8.0 g/dL ( red blood cell transfusion allow ) Hepatic ALT ≤ 5 time upper limit normal ( ULN ) Albumin ≥ 2 g/dL Bilirubin ≤ 1.5 time ULN Renal Creatinine normal age OR Creatinine clearance OR radioisotope glomerular filtration rate ≥ 70 mL/min/1.73 m^2 Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No uncontrolled infection PRIOR CONCURRENT THERAPY : Biologic therapy At least 7 day since prior biologic therapy , include immunotherapy At least 3 month since prior stem cell transplantation No evidence active graftvshost disease No concurrent biologic therapy No concurrent immunotherapy Chemotherapy Recovered prior chemotherapy At least 6 week since prior nitrosoureas Prior therapy hydroxyurea allow 24 hour initiation study drug No concurrent chemotherapy Endocrine therapy Concurrent hydrocortisone corticosteroid allow premedications prior blood product transfusion patient prior severe allergic reaction Radiotherapy Recovered prior radiotherapy No concurrent radiotherapy Surgery Not specify Other No concurrent anticancer agents No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>childhood acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
</DOC>